Clinical trials in patients with advanced melanomas showed that riluzole, a mGluR1 signaling inhibitor, can induce tumor regression through the inhibition of mitogen-activated protein kinase and phosphoinositide 3-kinase/protein kinase B [100,110,117]. Here, AKT1 is linked to melanoma.